VIDEO: Directional deep brain stimulation: novel treatment options for all Parkinson’s patients
sponsored by Boston Scientific
Author: SPONSOREDPublished: 4 October 2017
Prep: Cook: Serves:
Watch deep brain stimulation (DBS) experts Professor Pollo, Professor Timmermann, Professor Visser-Vanderwalle and Professor Volkmann explain the benefits of novel directional DBS systems for improved symptom control and fewer side effects
Every human brain is unique and every course of Parkinson’s disease has its own characteristics. In deep brain stimulation (DBS) therapy, physicians aim to target a very specific part of the brain – the subthalamic nucleus – in order to mitigate Parkinson’s symptoms.
Up until now, conventional DBS systems only allowed for stimulation with ring electrodes. With these electrodes, stimulation took the form of a ring around the electrode in the lead that was implanted into the patient’s brain. This meant that while physicians tried to target a very specific area of the brain, they always ran the risk of stimulating its neighbouring regions – since they could not steer the stimulation precisely. Unintended and unwanted stimulation could cause side effects such as speech problems.
The latest generation of DBS devices allow physicians to precisely steer the stimulation to target one specific area of the brain – significantly reducing side effects from unwanted stimulation. Our directional DBS systems use novel lead designs with segmented electrodes that allow the activation of individual electrode contacts. In addition, the technology in the pulse generator that powers the leads – the Multiple Independent Current Control (MICC) technology – allows the physician to specify exactly the amount of current needed for every contact of the electrode.
Through activating specific electrode contacts, and defining the amount of stimulation for each contact, stimulation precision is significantly increased. It is similar to shining a light on a specific spot with a flashlight. With the new systems, physicians now have full control of the stimulation steering and an increased set of stimulation options.
About deep brain stimulation (DBS) therapy
DBS uses a stimulator that is implanted into the patient’s chest. The stimulator sends mild electrical impulses to specific areas of the brain via thin wires called leads. This stimulation may help improve day-to-day experiences for people living with movement disorders such as Parkinson’s disease, dystonia, or essential tremor.
For comprehensive information on deep brain stimulation and Parkinson’s, please visit the EPDA website.
This article is sponsored by Boston Scientific. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Brian Grant on living with Parkinson’s: “My biggest fear is embarrassing my kids”
How Parkinson’s has changed the relationship he has with his kids
3 days ago
Breath test “detects early-stage Parkinson’s”
Scientists from Technion – Israel Institute of Technology, Israel, have developed a breath test that they claim can detect early-stage Parkinson’s. As part of a study – published in medical journal ‘ACS Chemical Neuroscience’ – scientists used a breathing device to analyse the breath of 29 participants who had been diagnosed with Parkinson’s. In addition, scientists also examined the breath of 19 people in the same age group who did not have the condition. The results suggested the breath test had an accuracy of 81% – leading scientists to believe the device could be used as a portable screening tool without assistance from a medical professional. The authors of the study said: “Early diagnosis of Parkinson’s disease is important because it affects the choice of therapy and is subject to a relatively high degree of error.”
Scientists at a Japanese university will carry out a world-first clinical trial transplanting reprogrammed stem cells into the brains of seven people with Parkinson’s. Researchers believe the process – which was tested on monkeys last year – will allow the brain to create dopamine to counter the effects of Parkinson’s. Shinya Yamanaka, who is working on the study and won the Nobel Prize in 2012 for his work with stem cells, said: “We intend to carry on conducting our research carefully, yet expeditiously, in coordination with Kyoto University Hospital, so that new treatment will be brought to patients as soon as possible.” Researchers are hoping to create a treatment that will be covered by national health insurance in Japan.
Researchers at the Boston University School of Medicine, Massachusetts, US have found a link between engaging in contact sports such as American football, boxing and ice hockey – and developing neurodegenerative conditions, including Parkinson’s. The study – published in the ‘Journal of Neuropathology and Experimental Neurology’ – found that engaging in contact sports increased the risk of developing Lewy body disease – a condition which is caused by deposits of protein forming inside brain cells and can lead to Parkinson’s. After studying 694 brains, researchers concluded that those who had played contact sports for more than eight years developed neurological conditions at six times the rate of those that did not. Dr Thor Stein, the author of the study, said: “We found the number of years an individual was exposed to contact sports, including football, ice hockey, and boxing, was associated with Parkinsonism and dementia.”